Durvalumab - Wikipedia
WEBDurvalumab, sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 ( PD-L1 ) with the PD-1 (CD279).
Durvalumab - NCI - National Cancer Institute
WEBDurvalumab is approved to treat adults with: Biliary tract cancer, including cholangiocarcinoma and gallbladder cancer, that has spread. It is used with gemcitabine hydrochloride and cisplatin. Hepatocellular carcinoma (a type of liver cancer) that cannot be removed by surgery. It is used with tremelimumab-actl.
Durvalumab Uses, Side Effects & Warnings - Drugs.com
WEBNov 14, 2023 · What is durvalumab? Durvalumab is used to treat cancer of the lungs, bladder, or urinary tract. Durvalumab is sometimes given when the cancer has spread to other parts of the body or cannot be removed with surgery, or when other treatments did not work or have stopped working.
Immunotherapy for BTC, uHCC, NSCLC & ES-SCLC – IMFINZI® (durvalumab)
WEBIMFINZI® (durvalumab) is an immunotherapy approved to treat patients with unresectable hepatocellular carcinoma, bile duct cancer, gallbladder cancer, unresectable Stage 3 NSCLC, Stage 4 NSCLC, and extensive-stage SCLC.
Durvalumab (Intravenous Route) - Mayo Clinic
WEBFeb 1, 2024 · Descriptions. Durvalumab injection is used to treat non-small cell lung cancer (NSCLC) that has not spread and cannot be removed by surgery in patients who have received other cancer medicines (eg, platinum) and radiation treatment for their NSCLC. This medicine is also used in combination with etoposide and either carboplatin or …
Durvalumab: Uses, Interactions, Mechanism of Action | DrugBank …
WEBDurvalumab is an antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer. Brand Names. Imfinzi. Generic Name. Durvalumab. DrugBank Accession Number. DB11714. Background.
Durvalumab (Imfinzi) | FDA
WEBThe recommended dose of durvalumab is 10 mg/kg, administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity. Full prescribing...
Imfinzi (durvalumab) dosing, indications, interactions, adverse …
WEBdurvalumab (Rx) Brand and Other Names: Imfinzi. Classes: PD-1/PD-L1 Inhibitors. Print. Dosing & Uses. AdultPediatric. Dosage Forms & Strengths. injectable solution. 50mg/mL (2.4-mL, 10-mL...
Perioperative Durvalumab for Resectable Non–Small-Cell Lung …
WEBOct 23, 2023 · Durvalumab is a selective, high-affinity, human IgG1 monoclonal antibody that inhibits interaction of PD-L1 with PD-1 and CD80 by binding to PD-L1. 28 Findings from the PACIFIC trial have...
Durvalumab (Imfinzi) | Cancer information | Cancer Research UK
WEBDurvalumab is a type of immunotherapy. It is a treatment for lung cancer. Find out about how you have it, possible side effects and other important information.
Skip to content